// App-Quantinova.ai

EP1085 : CLINICAL BENEFIT OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB IN JAK INHIBITOR TREATMENT NAÏVE MYELOFIBROSIS PATIENTS: INTERIM EFFICACY SUBGROUP ANALYSIS FROM ARM 3 OF MANIFEST PH2 STUDY

Researchers

Presenter

  • Marina Kremyanskaya

Principal Investigators

  • Andrea Patriarca

  • Vikas Gupta

  • Timothy Devos

  • Claire Harrison

  • Francesco Passamonti

  • Raajit Rampal

  • Adam Mead

  • Joseph Scandura

  • Gabriela Hobbs

  • Moshe Talpaz

  • Nikki Granacher

  • Tim Somervaille

  • Ronald Hoffman

  • Prithviraj Bose

  • Gozde Colak

  • James Shao

  • Jike Cui

  • Suresh Bobba

  • Katarina Luptakova

  • Srdan Verstovsek

  • Francesca Palandri

Medical Centers

  • Constellation Pharmaceuticals,Cambridge,United States

  • University of Insubria, University Hospital Ospedale di Circolo,Varese,Italy

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Division of Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

  • University of Michigan Cancer Center,Ann Arbor,United States

  • Azienda Ospedaliero Universitaria Maggiore della Carità di Novara SCDU Ematologia, Novara, Italy

  • Institute of Hematology “L. and A. Seràgnoli”, Sant’Orsola-Malpighi University Hospital,Bologna,Italy

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Farr Institute, Uni- versity of Manchester, Manchester, United Kingdom

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Ziekenhuis Netwerk Antwerpen Stuivenberg,Antwerp,Belgium

  • University Hospitals Leuven and Laboratory of Molecular Immunology (Rega Institute), KU Leuven,Leuven,Belgio

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

Locations

  • United States

  • Italy

  • United Kingdom

  • Belgium

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • Janus kinase

Drug/Treatment

  • Ruxolitinib phosphate

  • CPI-0610

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved